Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain

Primary immunodeficiency diseases (PID), which are comprised of over 400 genetic disorders, occur when a component of the immune system is diminished or dysfunctional. Patients with PID who require immunoglobulin (IG) replacement therapy receive intravenous IG (IVIG) or subcutaneous IG (SCIG), each...

Descripción completa

Detalles Bibliográficos
Autores: Alsina, Laia, Montoro, J. Bruno, Moral Moral, Pedro, Neth, Olaf, Ortiz-Pica, Marta, Sánchez-Ramón, Silvia, Presa, María, Oyagüez, Itziar, Casado, Miguel Ángel, González-Granado, Luis
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/305172
Acceso en línea:http://hdl.handle.net/10261/305172
https://api.elsevier.com/content/abstract/scopus_id/85115225624
Access Level:acceso abierto
Palabra clave:Cost-minimization analysis
Immune system
Immunoglobulin replacement therapy
Intravenous immunoglobulin
Primary immunodeficiency disease
Subcutaneous immunoglobulin
id ES_e31bdbf666b9ee1fe0fbc27b59df11dc
oai_identifier_str oai:digital.csic.es:10261/305172
network_acronym_str ES
network_name_str España
repository_id_str
spelling Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in SpainAlsina, LaiaMontoro, J. BrunoMoral Moral, PedroNeth, OlafOrtiz-Pica, MartaSánchez-Ramón, SilviaPresa, MaríaOyagüez, ItziarCasado, Miguel ÁngelGonzález-Granado, LuisCost-minimization analysisImmune systemImmunoglobulin replacement therapyIntravenous immunoglobulinPrimary immunodeficiency diseaseSubcutaneous immunoglobulinPrimary immunodeficiency diseases (PID), which are comprised of over 400 genetic disorders, occur when a component of the immune system is diminished or dysfunctional. Patients with PID who require immunoglobulin (IG) replacement therapy receive intravenous IG (IVIG) or subcutaneous IG (SCIG), each of which provides equivalent efficacy. We developed a cost-minimization model to evaluate costs of IVIG versus SCIG from the Spanish National Healthcare System perspective. The base case modeled the annual cost per patient of IVIG and SCIG for the mean doses (per current expert clinical practice) over 1 year in terms of direct (drug and administration) and indirect (lost productivity for adults and parents/guardians of pediatric patients) costs. It was assumed that all IVIG infusions were administered in a day hospital, and 95% of SCIG infusions were administered at home. Drug costs were calculated from ex-factory prices obtained from local databases minus the mandatory deduction. Costs were valued on 2018 euros. The annual modeled costs were €4,266 lower for patients with PID who received SCIG (total €14,466) compared with those who received IVIG (total €18,732). The two largest contributors were differences in annual IG costs as a function of dosage (– €1,927) and hospital administration costs (– €2,688). However, SCIG incurred training costs for home administration (€695). Sensitivity analyses for two dose-rounding scenarios were consistent with the base case. Our model suggests that SCIG may be a cost-saving alternative to IVIG for patients with PID in Spain.Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This study was funded by Shire, a Takeda company.Peer reviewedSpringerCSIC - Unidad de Recursos de Información Científica para la Investigación (URICI)Takeda Pharmaceutical CompanyConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202320232022info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/305172https://api.elsevier.com/content/abstract/scopus_id/85115225624reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)InglésThe underlying dataset has been published as supplementary material of the article in the publisher platform at DOI 10.1007/s10198-021-01378-xhttps://doi.org/10.1007/s10198-021-01378-xSíinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3051722026-05-22T06:33:51Z
dc.title.none.fl_str_mv Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain
title Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain
spellingShingle Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain
Alsina, Laia
Cost-minimization analysis
Immune system
Immunoglobulin replacement therapy
Intravenous immunoglobulin
Primary immunodeficiency disease
Subcutaneous immunoglobulin
title_short Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain
title_full Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain
title_fullStr Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain
title_full_unstemmed Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain
title_sort Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain
dc.creator.none.fl_str_mv Alsina, Laia
Montoro, J. Bruno
Moral Moral, Pedro
Neth, Olaf
Ortiz-Pica, Marta
Sánchez-Ramón, Silvia
Presa, María
Oyagüez, Itziar
Casado, Miguel Ángel
González-Granado, Luis
author Alsina, Laia
author_facet Alsina, Laia
Montoro, J. Bruno
Moral Moral, Pedro
Neth, Olaf
Ortiz-Pica, Marta
Sánchez-Ramón, Silvia
Presa, María
Oyagüez, Itziar
Casado, Miguel Ángel
González-Granado, Luis
author_role author
author2 Montoro, J. Bruno
Moral Moral, Pedro
Neth, Olaf
Ortiz-Pica, Marta
Sánchez-Ramón, Silvia
Presa, María
Oyagüez, Itziar
Casado, Miguel Ángel
González-Granado, Luis
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv CSIC - Unidad de Recursos de Información Científica para la Investigación (URICI)
Takeda Pharmaceutical Company
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Cost-minimization analysis
Immune system
Immunoglobulin replacement therapy
Intravenous immunoglobulin
Primary immunodeficiency disease
Subcutaneous immunoglobulin
topic Cost-minimization analysis
Immune system
Immunoglobulin replacement therapy
Intravenous immunoglobulin
Primary immunodeficiency disease
Subcutaneous immunoglobulin
description Primary immunodeficiency diseases (PID), which are comprised of over 400 genetic disorders, occur when a component of the immune system is diminished or dysfunctional. Patients with PID who require immunoglobulin (IG) replacement therapy receive intravenous IG (IVIG) or subcutaneous IG (SCIG), each of which provides equivalent efficacy. We developed a cost-minimization model to evaluate costs of IVIG versus SCIG from the Spanish National Healthcare System perspective. The base case modeled the annual cost per patient of IVIG and SCIG for the mean doses (per current expert clinical practice) over 1 year in terms of direct (drug and administration) and indirect (lost productivity for adults and parents/guardians of pediatric patients) costs. It was assumed that all IVIG infusions were administered in a day hospital, and 95% of SCIG infusions were administered at home. Drug costs were calculated from ex-factory prices obtained from local databases minus the mandatory deduction. Costs were valued on 2018 euros. The annual modeled costs were €4,266 lower for patients with PID who received SCIG (total €14,466) compared with those who received IVIG (total €18,732). The two largest contributors were differences in annual IG costs as a function of dosage (– €1,927) and hospital administration costs (– €2,688). However, SCIG incurred training costs for home administration (€695). Sensitivity analyses for two dose-rounding scenarios were consistent with the base case. Our model suggests that SCIG may be a cost-saving alternative to IVIG for patients with PID in Spain.
publishDate 2022
dc.date.none.fl_str_mv 2022
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/305172
https://api.elsevier.com/content/abstract/scopus_id/85115225624
url http://hdl.handle.net/10261/305172
https://api.elsevier.com/content/abstract/scopus_id/85115225624
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv The underlying dataset has been published as supplementary material of the article in the publisher platform at DOI 10.1007/s10198-021-01378-x
https://doi.org/10.1007/s10198-021-01378-x
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422471627669504
score 15.811543

Similares en LA Referencia